Diaceutics Regulatory News (DXRX)

Diaceutics PLC

("Diaceutics" or the "Group")

Belfast investor presentation

As stated on 17 February 2020, Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announced that it would hold a presentation for investors on Monday, 6 April 2020 in Belfast City. The presentation was to be given jointly by Diaceutics and Fusion Antibodies plc, the specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.

The decision has been made by the management teams of both companies to postpone this event. If you would like to view the Group's very positive final results issued earlier this week, please see the attached link: https://polaris.brighterir.com/public/diaceutics/news/rns/story/xl3ov9x.

If you have any questions, please contact the team at Walbrook PR on 0207 933 8780 or at diaceutics@walbrookpr.com.

Enquiries:

About Diaceutics

Diaceutics PLC is diagnostic commercialisation company. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com